Dong-A ST seeks approval for Aranesp biosimilar in Japan - (The Korea Herald via NewsPoints Desk)

  • Dong-A ST said its partner Sanwa Kagaku Kenkyusho has requested approval to launch a biosimilar of Amgen and Kyowa Hakko Kirin's anaemia therapy Aranesp in Japan, The Korea Herald reported.

  • If approved, Dong-A ST will manufacture the therapy, named DA-3880, while Sanwa Kagaku Kenkyusho will be responsible for distribution.

  • "The Japanese biosimilar market is expected to increase significantly due to the growing needs for medical expense deduction as the country is inching closer toward a super-aged society," a Dong-A ST official commented.

  • Sales of Aranesp in Japan reached $439 million last year, with global revenue equalling $3 billion.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.

Reference Articles